Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6)

Agarwal, Kosh; Brown, R.S.; Dumas, Emily O.; McCaughan, G.W.; Samuel, Didier; Terrault, Norah A.; Brown, Kimberly; Mantry, Parvez S.; Berenguer, Marina; Kwo, P.; O’Leary, Jacqueline G.; Charafeddine, Mariem; Pilot‐Matias, Tami; Shuster, Diana L.; Lü, Wenjing; Enejosa, Jeffrey; Cohen, David E.; Mariñó, Zoe; Forns, Xavier

doi:10.1016/s0168-8278(17)31461-7

Journal of Hepatology

2017

DOI: 10.1016/s0168-8278(17)31461-7

|View full text |Cite

Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6)

Kosh Agarwal¹,

R.S. Brown²,

Emily O. Dumas³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy

Cohen

Liapakis

2018

Seminars in Dialysis

View full text Add to dashboard Cite

Hepatitis C direct acting antiviral (DAA) therapy has evolved so that infected patients with advanced chronic kidney disease (CKD) can now anticipate the opportunity for sustained virologic response equivalent to that of the broader population of patients with hepatitis C. This has revolutionized the field of transplantation as it relates to renal transplant candidates with hepatitis C and the use of grafts from hepatitis C virus (HCV) viremic donors. In treating this population of patients, special consideration must be given to the timing of anti-viral therapy and drug-drug interactions. Herein we review the pharmacokinetics of HCV DAA therapy in the setting of CKD and chronic renal replacement therapy. Highlighted are drug/drug interactions with special attention to therapies utilized in advanced CKD and immunosuppressants.

show abstract

Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy

Cohen

Liapakis

2018

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6)

Cited by 1 publication

References 0 publications

Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy

Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy

Contact Info

Product

Resources

About